Short-bowel syndrome is the most common cause of intestinal failure. Until recently, management options were limited to dietary support, anti-secretory drugs and anti-motility agents. The introduction of GLP-2 analogues have drastically changed the field, offering disease-modifying therapy which can lead to reduction of parenteral support. However, several questions remain: which is the ideal target population? When should treatment be started? Can the treatment frequency be reduced after full weaning? And how should the care for a patient treated with GLP-2 analogues be embedded in a multidisciplinary approach?
Prof Vanuytsel is a consultant gastro-enterologist at the University Hospitals Leuven with a clinical focus on intestinal failure, clinical nutrition and functional gastro-intestinal disorders. He is the co-founder and medical head of the Leuven Intestinal Failure and Transplant center (LIFT), which represents the largest intestinal failure and only bowel and multivisceral transplant center in Belgium. He is also assistant professor at the KU Leuven and his research interests include the pathophysiology and treatment of functional gastrointestinal disorders and intestinal failure and transplantation. He has published more than 120 original peer-reviewed papers and supervises 16 PhD students. He is the editor in chief of the Acta Gastroenterologica Belgica.
Palle Bekker Jeppesen is Clinical Professor at Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; Head of Department of Intestinal Failure and Intestinal Diseases at Rigshospitalet in Copenhagen, Denmark, and he is also an Affiliate Professor in the Department of Nutrition, Exercise and Sports at the unit for Clinical and Experimental Nutrition, University of Copenhagen.
His major research interests include patients with short bowel syndrome and intestinal failure with a recent focus on novel therapies for their management, rehabilitation and care. He has been instrumental in the conduction of phase 2 and 3 trials in all GLP-2 analogs.
Professor Jeppesen graduated in medicine from the University of Copenhagen, Denmark, in 1989 and completed his residency in medical gastroenterology at the Rigshospitalet in Copenhagen. He completed his PhD thesis, entitled The significance of the fatty acid chain-length for the clinical effect in the enteral and parenteral nutrition in patients with malabsorption in 1998 and his Doctor’s Degree, entitled Intestinal insufficiency and failure, in 2003.
PBJ has published more than 150 peer-reviewed papers and book chapters within this field.
PBJ has been a member of the Scientific Committee of the European Society of Nutrition and Metabolism (ESPEN) and currently holds a position in the Intestinal Rehabilitation and Transplantation (IRTA) Council.